POM-V Prescription Required Companion Animal

Meloxicam Ceva 0.5 mg/ml Oral Suspension for Cats

Active ingredient: Meloxicam

Form

Liquid

Species

Cats

Manufacturer

Ceva Sante Animale

VMD MA No.

14966/3005

What it's used for

Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. Allev...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Meloxicam Ceva 0.5 mg/ml Oral Suspension for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Alleviation of mild to moderate post-operative pain and inflammation following
surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.
Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders
in cats.

-
-
and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
-
any of the excipients.
-

Revised: September 2025
AN: 01833/2025

Cats:
Vomiting
, Diarrhoea
, Blood in faeces
,
Gastric ulceration
Appetite loss
, Apathy
Renal failure
Elevated liver enzymes
.
Very rare
(<1 animal / 10,000
animals treated, including
isolated reports):

Revised: September 2025
AN: 01833/2025
These side effects disappear following termination of the treatment but in very rare
cases may be serious or fatal.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the
national competent authority via the national reporting system. See also section
“Contact details” of the package leaflet for respective contact details.

None.

Special precautions for use in animals
If adverse reactions occur, treatment should be discontinued and the advice of a
veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of renal toxicity.
Post-operative pain and inflammation following surgical procedures:
In case additional pain relief is required, multimodal pain therapy should be
considered.
Chronic musculoskeletal disorders:
Response to long-term therapy should be monitored at regular intervals by a
veterinary surgeon.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Meloxicam and other non-steroidal anti-inflammatory drugs (NSAIDs) may cause
hypersensitivity (allergic reactions).
People with known hypersensitivity to NSAIDs should avoid contact with the
veterinary medicinal product.
Accidental ingestion of the product by a child may cause gastro-intestinal effects,
such as nausea and gastric pain.
Any uneaten medicated food must be disposed of immediately and the bowl washed
thoroughly.
Do not leave an unattended filled syringe in the sight or reach of children.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
This product can cause eye irritation. In case of contact with the eyes, immediately
rinse thoroughly with water.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
Other precautions
Not applicable.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances
with high protein binding may compete for binding and thus lead to toxic effects. The
veterinary medicinal product must not be administered in conjunction with other
NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic
drugs should be avoided.
Pre-treatment with anti-inflammatory substances may result in additional or
increased adverse effects and accordingly a treatment-free period with such
veterinary medicinal products should be observed for at least 24-hours before
commencement of treatment. The treatment-free period, however, should take into
account the pharmacological properties of the veterinary medicinal products used
previously.

This veterinary medicinal product does not require any special storage conditions.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.